Synlett 2015; 26(02): 228-232
DOI: 10.1055/s-0034-1379504
letter
© Georg Thieme Verlag Stuttgart · New York

Synthesis of the Novel Tetrahydropyrazolo[3,4-c]pyridin-5-one Scaffold

Nicholas J. Howe*
AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK   Email: nick.howe@astrazeneca.com
,
Kevin Blades
AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK   Email: nick.howe@astrazeneca.com
,
Gillian M. Lamont
AstraZeneca Oncology Innovative Medicines, Mereside, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK   Email: nick.howe@astrazeneca.com
› Author Affiliations
Further Information

Publication History

Received: 09 October 2014

Accepted after revision: 30 October 2014

Publication Date:
02 December 2014 (online)


Zoom Image

Abstract

We report an efficient synthesis of the novel 1,4,6,7-tetra­hydropyrazolo[3,4-c]pyridin-5-one scaffold with the potential for incorporation of alkyl or aryl substituents at the C-3 and N-6 positions. The route utilises a Dieckmann condensation to install the lactam ring, followed by a hydrazine cyclisation to build the fused pyrazole ring.

Supporting Information